OncLive - Clinical Oncology News, Cancer Expert Insights
OncLive - Clinical Oncology News, Cancer Expert Insights
Spotlight
CME Opportunities
Specialty
View MoreBreast CancerLung CancerGastrointestinal CancerGenitourinary CancersOvarian CancerProstate CancerMelanoma & Skin CancerMCLMPNCAR T-cell TherapyChronic Lymphocytic LeukemiaGynecologic OncologyHematologic OncologyImmuno-OncologyMultiple MyelomaUrothelial Cancer
News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Conferences
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
PartnersPublications
Resources
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Biomarker ConsortiumSubscribe
  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information

© 2025 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

Spotlight
  • CME Opportunities
SpecialtySee All >
  • Breast Cancer
  • Lung Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Ovarian Cancer
  • Prostate Cancer
  • Melanoma & Skin Cancer
  • MCL
  • MPN
  • CAR T-cell Therapy
  • Chronic Lymphocytic Leukemia
  • Gynecologic Oncology
  • Hematologic Oncology
  • Immuno-Oncology
  • Multiple Myeloma
  • Urothelial Cancer
OncLive SOSS
  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
  • MJHLS Brand Logo

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

Danielle M. Brander, MD, Duke Cancer Institute

  1. home

Articles

Relapsed/Refractory CLL Treatment: Addressing Unmet Needs

February 8th 2021

Frontline CLL Treatment: Addressing Unmet Needs

January 8th 2021

Allogeneic Transplantation for CLL

January 8th 2021

Relapsed/Refractory CLL: Repeat Molecular Testing

January 8th 2021

Therapeutic Sequencing in Relapsed/Refractory CLL

January 8th 2021

CLL Patient Management During COVID-19 and Telehealth

January 8th 2021

CLL Treatment Approaches During COVID-19

January 8th 2021

Frontline CLL: Treatment Algorithms

January 8th 2021

Minimal Residual Disease in CLL

January 8th 2021

Frontline CLL Treatment With Fixed-Duration Regimens

January 8th 2021

Anti-BCL2/CD20 Combination Therapy for Frontline CLL

January 8th 2021

Anti-CD20/BTKi Therapy for Frontline CLL

January 8th 2021

BTK Monotherapy for Frontline CLL

January 8th 2021

Selecting Frontline Therapy to Treat CLL

January 8th 2021